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9-39 (Ex-9) have demonstrated that a single dose of Ex-9 can prevent post-
prandial hypoglycemia, normalize beta cell function, and reduce neuroglyco-
penic symptoms in patients with PBH. We present interim data from the ﬁrst 
multi-dose, multi-day study aimed at evaluating the efﬁcacy, tolerability, and 
pharmacokinetic proﬁle of subcutaneous Ex-9 in patients with PBH.
In this Phase 2a, single-blind, multiple ascending dose study conducted 
at the Stanford University Clinical and Translational Research Unit, 11 par-
ticipants underwent a baseline oral glucose tolerance test (OGTT) followed 
by random assignment to up to 3 days of BID subcutaneous doses of Ex-9 
ranging from 0.05-0.45 mg/kg with a repeat OGTT on the ﬁnal day of dos-
ing. Treatment with Ex-9 reduced the magnitude of hypoglycemia at all dose 
levels. Participants receiving doses of ɗ 0.2 mg/kg did not require rescue, 
and on average achieved a 50 ± 13% reduction in peak insulin concentrations 
with a 44 ± 18% reduction in neuroglycopenic symptoms. These interim data 
provide preliminary evidence that multiple doses of Ex-9 prevent severe and 
symptomatic postprandial hypoglycemia in patients with PBH during OGTT.
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Differential Associations of Impaired Hypoglycemia Awareness 
and Severe Hypoglycemia with Cognition, Quality of Life, and Dis-
tress in T1D Adults
EDUARDO SEPULVEDA, DAVIDE CARVALHO, DANIELA SEIXAS, STEPHANIE 
A. AMIEL, SELENE VICENTE, Porto, Portugal, Coimbra, Portugal, London, United 
Kingdom
Impaired hypoglycemia awareness (IHA) affects 20% to 40% of T1D pa-
tients and increases risk of severe hypoglycemia (SH). IHA has been asso-
ciated with low concern about hypoglycemia, despite high risk of SH, and 
with reduced ability to change behavior to avoid future hypoglycemia. We 
assessed hypoglycemia awareness (HA) and sought correlations with cogni-
tion, quality of life (QoL), and distress in 85 T1D adults with HA and IHA. HA 
status was determined using the Gold Score (GS) and the Clarke score (CS), 
with ɗ4=IHA for each. SH was evaluated by 2 questions (3 and 4) included in 
the CS. All subjects completed the Montreal Cognitive Assessment (global 
cognition); the INECO Frontal Screening (executive functions); the Diabetes 
Health Proﬁle (DHP, QoL); and the Hospital Anxiety and Depression Scale. 
Participants’ mean±SD age and diabetes duration were 38.4±12.5 and 
19.1±11.7 years, respectively; 54.1% were male; median and interquartile 
ranges for GS and CS 3 [1-4] and 1 [0-3], respectively. 32% had IHA by GS 
and 17% by CS, the 2 scores correlating moderately (rs=0.58, P < 0.001). 86% 
of IHA patients by CS vs. only 41% with IHA by GS had had SH in the past 
6 months, with 50% vs. 19% reporting seizure, or parenteral treatment for 
SH in the last year and no reports of such SH in participants with IHA by GS 
only. Correlation analysis of the whole group showed that increased GS and 
CS associated with lower performance in naming subtest and higher barriers 
to activity in DHP. Only CS associated with higher psychological distress in 
DHP, and higher anxiety and depression, while 38% of subjects scoring posi-
tive for IHA with GS only had evidence of executive dysfunction.
In conclusion, people with T1D and IHA, at known high risk for SH, show 
evidence of impaired cognition and psychological distress. The association of 
a positive CS but not GS with increased psychological distress suggests the as-
sociation may be driven by SH, while IHA alone may drive executive dysfunction.
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Racial Differences in Emergency Department Visits for Hypoglyce-
mia in Older Insulin Recipients, 2004-2013
CHIN-LIN TSENG, ORYSYA SOROKA, LEONARD POGACH, East Orange, NJ
We evaluated annual trends in emergency department (ED) visits for hypogly-
cemia (HYPO) in veterans receiving Veteran Health Administration (VHA) care us-
ing linked VHA and Medicare databases. Patients on insulin and ɗ65 years were 
stratiﬁed by race/ethnicity and four comorbidity categories (cardio-vascular (CV), 
advanced diabetes complications (AD), diminished life expectancy, and mental 
health/neurologic). Patients on insulin increased from 55,882 (11.2% of older dia-
betes patients) in 2004 to 100,175 (15.5%) in 2013. 80-82% were white, 10-11% 
black, 5-6% Hispanic, and <2% women. 79-83% had ɗ1 comorbidity categories: 
AD only: 8-9%, CV only: 24-29%, AD and CV only: 16-21%. Cumulative ED visits 
were 37,494 (3,266-4,056/year) for 24,760 (2,563-3,266/year) unique patients; 
5,094 (14%) events had subsequent hospitalization. Rates declined from 2008 for 
all races/ethnicity (rate ratio: 0.65; 95% CI=0.62-0.68 from a Poisson regression). 
Blacks had higher rates than whites (58.5 vs. 37.5 events per 1,000 patients in 
2013). Compared to those without comorbidities (24.4 in 2013), rates were 46.4 
for AD only, 31.3 for CV only, 49.6 for AD and CV only, and 70.1 for having 3 or 
4 comorbidity categories in 2013. Racial differences persisted in all comorbid 
categories despite marked declines in HYPO_ED rates. We propose case man-
agement for high risk patients, especially minority groups.
Figure.
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Prediction of Hypoglycemia during Aerobic Exercise in Individuals 
with Type 1 Diabetes Using Decision Trees
RAVI REDDY, JOSEPH EL YOUSSEF, JESSICA R. CASTLE, PETER G. JACOBS, 
Portland, OR
Individuals with type 1 diabetes (T1D) indicate the fear of exercise related 
hypoglycemia as the major barrier to regular physical activity. There is current-
ly no validated prediction algorithm that can help these individuals ascertain 
the risk of hypoglycemia prior to the start of aerobic exercise. We developed 
and evaluated 3 separate prediction algorithms with increasing levels of com-
plexity to identify the risk of hypoglycemia at the start of exercise. A meta-
data set was used from over 130 observations of in-clinic aerobic exercise 
in 37 adults with T1D from 3 different studies (17M; weight, 72±12 kg; age, 
33±6 years) to train and validate the prediction algorithms. Subjects performed 
either moderate or mild aerobic exercise at different times of the day (morn-
ing, midafternoon, or late afternoon) and exercised for durations ranging from 
25 min to 45 min. We developed and tested the following three prediction 
algorithms using a ten-fold cross-validation approach and included anthropo-
morphic, exercise, glucose and insulin features. Model 1: Simple decision tree 
model. Model 2: Complex decision tree model. Model 3: Random forest model 
for use in automated insulin delivery systems
Table.
Classiﬁer Number of 
features
Accuracy 
(%)
Sensitivity 
(%)
Speciﬁcity 
(%)
Model 1 2 80.00 72.92 84.15
Model 2 5 83.85 85.42 82.93
Model 3 8 97.69 100 96.34
After further validation, these models could potentially be used by both 
artiﬁcial pancreas and decision support systems to help people with T1D 
avoid exercise related hypoglycemia.
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Suppressed Catecholamine Release following Recurrent Hypogly-
cemia Involves Altered Adrenal Function
YUNBING MA, QIAN WANG, MATTHEW WHIM, New Orleans, LA
Insulin-induced hypoglycemia activates the counter-regulatory response 
(CRR), a hormonal and neuronal mechanism that restores euglycemia. A major 
component of the CRR is the release of epinephrine from neuroendocrine chro-
mafﬁn cells in the adrenal medulla. Epinephrine acts on a variety of target tissues 
including the liver and adipose tissue to increase glucose production. However, 
with repeated activation of the CRR, epinephrine release becomes progressively 
impaired. Although the reasons are not clear this could involve central or periph-
eral mechanisms or a combination of the two. To determine whether the altered 
CRR involves a change in adrenal function we quantiﬁed catecholamine release 
from chromafﬁn cells from (i) control mice; (ii) mice exposed to one episode of in-
sulin-induced hypoglycemia (IIH: blood glucose < 60 mg/dl) and (iii) mice exposed 
to three episodes of insulin-induced hypoglycemia. Catecholamine release was 
evoked optogenetically from single chromafﬁn cells in vitro isolated from THcre 
x ChR (tdTomato) mice. Secretion was triggered by a train of light ﬂashes and 
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